Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned

 
• By Sten Stovall

UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.

Incubator Fund Arix takes an 11% stake and board seat at Pharmaxis • Source: Shutterstock

More from Financing

More from Business